Compare VENUS REMEDIES with SHASUN PHARMA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

VENUS REMEDIES vs SHASUN PHARMA - Comparison Results

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    VENUS REMEDIES SHASUN PHARMA VENUS REMEDIES/
SHASUN PHARMA
 
P/E (TTM) x -1.1 123.9 - View Chart
P/BV x 0.1 8.5 0.9% View Chart
Dividend Yield % 0.0 0.2 -  

Financials

 VENUS REMEDIES   SHASUN PHARMA
EQUITY SHARE DATA
    VENUS REMEDIES
Mar-18
SHASUN PHARMA
Mar-14
VENUS REMEDIES/
SHASUN PHARMA
5-Yr Chart
Click to enlarge
High Rs12694 133.7%   
Low Rs6146 134.0%   
Sales per share (Unadj.) Rs301.8214.2 140.9%  
Earnings per share (Unadj.) Rs-24.95.3 -466.1%  
Cash flow per share (Unadj.) Rs2.515.8 16.1%  
Dividends per share (Unadj.) Rs01.00 0.0%  
Dividend yield (eoy) %01.4 0.0%  
Book value per share (Unadj.) Rs293.353.3 549.8%  
Shares outstanding (eoy) m12.3456.62 21.8%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.30.3 94.9%   
Avg P/E ratio x-3.813.1 -28.7%  
P/CF ratio (eoy) x36.74.4 831.6%  
Price / Book Value ratio x0.31.3 24.3%  
Dividend payout %018.7 0.0%   
Avg Mkt Cap Rs m1,1543,958 29.2%   
No. of employees `0000.9NA-   
Total wages/salary Rs m3932,164 18.2%   
Avg. sales/employee Rs Th4,026.1NM-  
Avg. wages/employee Rs Th425.0NM-  
Avg. net profit/employee Rs Th-331.8NM-  
INCOME DATA
Net Sales Rs m3,72412,127 30.7%  
Other income Rs m23229 9.8%   
Total revenues Rs m3,74712,356 30.3%   
Gross profit Rs m3951,009 39.1%  
Depreciation Rs m338594 57.0%   
Interest Rs m354415 85.4%   
Profit before tax Rs m-275230 -119.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m00 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m32-73 -43.5%   
Profit after tax Rs m-307302 -101.6%  
Gross profit margin %10.68.3 127.4%  
Effective tax rate %-11.5-31.7 36.3%   
Net profit margin %-8.22.5 -330.8%  
BALANCE SHEET DATA
Current assets Rs m2,6386,884 38.3%   
Current liabilities Rs m2,3058,456 27.3%   
Net working cap to sales %8.9-13.0 -69.0%  
Current ratio x1.10.8 140.6%  
Inventory Days Days13562 219.8%  
Debtors Days Days46108 43.1%  
Net fixed assets Rs m4,8714,970 98.0%   
Share capital Rs m123113 108.9%   
"Free" reserves Rs m3,4962,875 121.6%   
Net worth Rs m3,6193,020 119.8%   
Long term debt Rs m1,3741,817 75.6%   
Total assets Rs m7,50913,347 56.3%  
Interest coverage x0.21.6 14.4%   
Debt to equity ratio x0.40.6 63.1%  
Sales to assets ratio x0.50.9 54.6%   
Return on assets %0.65.4 11.7%  
Return on equity %-8.510.0 -84.8%  
Return on capital %1.613.3 11.9%  
Exports to sales %046.4 0.0%   
Imports to sales %13.914.2 97.4%   
Exports (fob) Rs mNA5,622 0.0%   
Imports (cif) Rs m5171,728 29.9%   
Fx inflow Rs m05,843 0.0%   
Fx outflow Rs m5172,173 23.8%   
Net fx Rs m-5173,669 -14.1%   
CASH FLOW
From Operations Rs m514398 129.4%  
From Investments Rs m-123-1,635 7.5%  
From Financial Activity Rs m-3871,309 -29.6%  
Net Cashflow Rs m471 5.9%  

Share Holding

Indian Promoters % 32.9 39.2 83.8%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.2 3.6 5.0%  
FIIs % 0.6 17.6 3.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 66.4 39.6 167.7%  
Shareholders   20,121 20,750 97.0%  
Pledged promoter(s) holding % 36.4 12.3 295.9%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare VENUS REMEDIES With:   GSK PHARMA  JUBILANT LIFE SCIENCES  DISHMAN PHARMA  PIRAMAL ENTERPRISES  NATCO PHARMA  

Compare VENUS REMEDIES With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Strengthening Rupee, Inflation & Factory Output Data, and Top Stocks in Action Today(Pre-Open)

On Friday, Indian share markets witnessed most of the buying interest during closing hours and ended on a strong note.

Related Views on News

VENUS REMEDIES Announces Quarterly Results (4QFY19); Net Profit Down 11.1% (Quarterly Result Update)

Jun 12, 2019 | Updated on Jun 12, 2019

For the quarter ended March 2019, VENUS REMEDIES has posted a net profit of Rs 104 m (down 11.1% YoY). Sales on the other hand came in at Rs 864 m (down 7.3% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

VENUS REMEDIES Announces Quarterly Results (3QFY19); Net Profit Down 2301.8% (Quarterly Result Update)

Feb 22, 2019 | Updated on Feb 22, 2019

For the quarter ended December 2018, VENUS REMEDIES has posted a net profit of Rs 119 m (down 2301.8% YoY). Sales on the other hand came in at Rs 691 m (down 25.8% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

VENUS REMEDIES 2017-18 Annual Report Analysis (Annual Result Update)

Dec 21, 2018 | Updated on Dec 21, 2018

Here's an analysis of the annual report of VENUS REMEDIES for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of VENUS REMEDIES. Also includes updates on the valuation of VENUS REMEDIES.

VENUS REMEDIES Announces Quarterly Results (2QFY19); Net Profit Down 16.3% (Quarterly Result Update)

Nov 23, 2018 | Updated on Nov 23, 2018

For the quarter ended September 2018, VENUS REMEDIES has posted a net profit of Rs 8 m (down 16.3% YoY). Sales on the other hand came in at Rs 809 m (down 10.6% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

VENUS REMEDIES Announces Quarterly Results (1QFY19); Net Profit Down 756.1% (Quarterly Result Update)

Aug 20, 2018 | Updated on Aug 20, 2018

For the quarter ended June 2018, VENUS REMEDIES has posted a net profit of Rs 56 m (down 756.1% YoY). Sales on the other hand came in at Rs 655 m (down 16.2% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

More Views on News

Most Popular

Buying these Eight Stocks is Like Owning Your Own Business(Profit Hunter)

Sep 5, 2019

Everyone dreams of owning a business. Here is your chance.

7 Stocks to Buy in the Market Today(The 5 Minute Wrapup)

Sep 5, 2019

The stock market had a four-year bull run starting September 2013. Are we seeing a similar pattern now?

Don't Buy Lakshmi Vilas Bank...Buy this Private Sector Bank with 74% Upside(The 5 Minute Wrapup)

Sep 4, 2019

Lakshmi Vilas Bank is in a vicious cycle. The stock is already down 57% in 2019. Despite this, the retail investors increased their holding.

Insider Buying Alert: Promoters Increase Stake in 8 High-Quality Smallcaps(Profit Hunter)

Sep 3, 2019

Insiders have increased their stakes in eight Hidden Treasure recommendations. Should you follow them?

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

VENUS REMEDIES SHARE PRICE


Sep 13, 2019 (Close)

TRACK VENUS REMEDIES

  • Track your investment in VENUS REMEDIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON VENUS REMEDIES

VENUS REMEDIES 8-QTR ANALYSIS

COMPARE VENUS REMEDIES WITH

MARKET STATS